Our top pick for
PPD Inc is a drug manufacturers-specialty & generic business based in the US. PPD shares (PPD) are listed on the NASDAQ and all prices are listed in US Dollars. PPD employs 30,000 staff and has a trailing 12-month revenue of around $5.9 billion.
|52-week range||$46.78 - $47.41|
|50-day moving average||$47.14|
|200-day moving average||$45.20|
|Wall St. target price||$47.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.01|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-09-23)||N/A|
|1 month (2022-08-31)||N/A|
|3 months (2022-06-30)||N/A|
|6 months (2022-03-31)||N/A|
|1 year (2021-10-04)||-100.00%|
|2 years (2020-10-02)||-100.00%|
|3 years (2019-09-30)||N/A|
|5 years (2017-09-30)||N/A|
Valuing PPD stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PPD's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PPD's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, PPD shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
PPD's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.541. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PPD's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
PPD's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $968.7 million.
The EBITDA is a measure of a PPD's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$5.9 billion|
|Operating margin TTM||11.37%|
|Gross profit TTM||$3 billion|
|Return on assets TTM||6.39%|
|Return on equity TTM||0%|
|Market capitalisation||$16.6 billion|
TTM: trailing 12 months
We're not expecting PPD to pay a dividend over the next 12 months.
PPD, Inc. , together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.